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Concept Evolution of Hemophagocytic
Syndrome
The concept of hemophagocytic syndrome (HPS)
evolved from the ambiguous histiocytic medullary
reticulosis (HMR) adopted by Scott and Robb-
Smith in 1939,1 to malignant histiocytosis pro-
posed by Rappaport in 1969,2 and finally to the
reactive nature of virus-associated HPS reported
by Risdall et al in 1979.3 Patients with this disorder
usually present with prolonged fever, hepatos-
plenomegaly, pancytopenia and coagulopathy. The
presence of atypical histiocytes (now, transformed
lymphoid cells) and macrophages with phagocyto-
sis of blood cells in bone marrow, lymph nodes,
and spleen establishes the diagnosis. The ambi-
guity in terminology, either with regard to benig-
nancy versus malignancy or cell origin, reflects our
lack of understanding of the exact nature of this
disease. HPS now represents a common epiphe-
nomenon of an immune disorder associated with
a diverse spectrum of underlying illnesses such as
viral infections, genetic disorders or malignancies.
Recently, the development of HPS in H5N1 avian
influenza virus infection has increased the urgency
to resolve the pathogenesis and therapy of HPS.4,5
Gene Mutations in Patients with 
Familial History of HPS
Our understanding of the pathogenesis of 
HPS comes mainly from studies on X-linked
lymphoproliferative disorder (XLP). XLP occurs
in children around 1 year of age.6 The discovery
of mutations in the SH2DIA/SAP gene, the nega-
tive regulator of the SLAM/ERK pathway for T cell
activation, represents a milestone in the patho-
genesis of XLP.7–9 Mutations in this gene lead to
overt T cell activation and secretion of interferon-γ
(IFN-γ) and tumor necrosis factor-α (TNF-α) in
response to Epstein-Barr virus (EBV) infection.10,11
Similar to XLP, cases of childhood HPS with fa-
milial clustering were found to have mutations
in perforins, Munc13-4 and others.12–14 They are
now classified as familial hemophagocytic lym-
phohistiocytosis (FHL). The mutations in the
perforin gene in FHL highlight the reduced innate
(NK) immunity in response to virus infections.
EBV-associated Hemophagocytic
Lymphohistiocytosis and Disease
Progression
In Asian countries and Taiwan, we noted the preva-
lence of a childhood entity of “HMR” or EBV-
associated hemophagocytic lymphohistiocytosis
(EBV-HLH) showing entirely similar findings to
XLP or FHL, except that no familial linkage was
demonstrated.15 In 1993, Kawaguchi et al and
our group noted that EBV unexpectedly infects T
cells in EBV-HLH, instead of the B cells in
XLP.15,16 EBV latent membrane protein-1 can trans-
duce the signals through TRAFs/NF-κB to activate
T cells through suppression of the SH2D1A/SAP
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gene, thereby providing a cross talk between XLP
and HLH.10 EBV causes the majority (60–80%)
of childhood HPS/HLH, but other viruses may
also be associated with HPS, usually with relatively
benign disease.
Based on the underlying immunopathogene-
sis associated with XLP, FHL and HLH, HPS can
be categorized into two main entities (Table 1).
FHL represents the primary or hereditary defect
of innate (NK or cytotoxic cells) response to virus
infections, while XLP and HLH represent the overt
adaptive Th1 response to virus infections. The com-
mon outcome in both categories is the enhanced
Th1 cytokine secretion, which will subsequently
activate macrophages.10,11 In severe viral infections
such as H5N1 avian influenza, NK cells were
noted to be reduced, leading to high viral repli-
cation and enhanced proinflammatory cytokine
secretion.4,5 Similar to the progression of XLP 
to Burkitt’s lymphoma, EBV-HLH may progress
to chronic active disease or T cell lymphoma in
about 10–20% of cases after therapy.17 EBV LMP-
1 could suppress TNF receptor-1 to survive from
TNF-α-induced apoptosis and then progress to T
cell lymphoma due to constitutive activation of
NF-κB signals.17
Mechanism of Blood Cell Phagocytosis
by Activated Macrophages in HPS
One important phenomenon of HPS is the en-
gulfment of blood cells by activated macrophages.
The phagocytic process is a non-random biologic
event and involves sophisticated ligand-receptor
interaction.18 Why hemophagocytosis occurs in
HPS is still mysterious. In an animal model of
rabbit HPS by Herpesvirus papio infection, we ob-
served the emergence of autoantibodies to red
cells as a precipitating factor for the subsequent
phagocytosis of red cells.19 The development of
autoantibodies is presumed to result from an
imbalanced switch between Th1 and Th2 cells,
leading to the emergence of polyclonal autoreac-
tive B cell response and autoantibody production.
Diagnosis and Therapy of HPS
In the past 10 years, we have witnessed the im-
proved survival of HPS patients for several reasons.
First, the proposal of the criteria guidelines by
the International Society of Histiocytes (Table 2)
has contributed significantly to the diagnosis and
therapy of HPS patients.14 The current regimens
are designed to control T cell activation (steroids,
cyclosporine, etoposide) and macrophage activa-
tion (intravenous immunoglobulin, etoposide) in
HPS. Bone marrow transplantation is recom-
mended for patients with hereditary disorders such
as XLP or FHL.
Challenging Issues in HPS
Considering the high mortality of HPS and the
potential threat of H5N1 avian influenza, proper
management of patients with HPS is becoming a
challenging issue. To clarify the nature of under-
lying diseases remains the critical event. How-
ever, the common clinical presentations and
rapidly progressive diseases of HPS usually make
the early recognition of HPS difficult. Rapid tests
for viral etiology using a combination of serologic
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Table 1. A comprehensive classification of
hemophagocytic syndrome (HPS)
Reduced or absent innate immunity (NK/CTL)
associated with HPS
Primary or familial: FHL1-4 (mutations in perforin, 
Munc13-4, others)
Severe viral infections with reduced NK activities: 
H5N1, dengue, adenovirus
HPS associated with overt adaptive T cell (Th1)
response
Primary or familial: XLP (SH2D1A/SAP gene 
mutations)
EBV-HLH (EBV infections of T cells)
Autoimmune disorders (lupus erythematosus)?
Others: malignancy (solid tumor)-associated HPS
FHL = familial hemophagocytic lymphohistiocytosis; XLP = X-linked
lymphoproliferative disorder; EBV-HLH = Epstein-Barr virus-
associated hemophagocytic lymphohistiocytosis.
and molecular tests should establish the etiology
in the majority of cases. Finally, an ideal regimen
for the control of HPS, especially the management
of chronic active or relapsing diseases, remains to
be developed. Since NF-κB plays a pivotal role in
the initiation of proinflammatory cytokine storm
in HPS,17,20 NF-κB inhibitors or peroxisome pro-
liferator-activated receptor agonists are potential
agents to be developed.21,22
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Table 2. New diagnostic guidelines for hemophagocytic lymphohistiocytosis (HLH-04)
The diagnosis of HLH can be established if criteria for either molecular diagnosis or clinical diagnosis are fulfilled:
 A molecular diagnosis consistent with hereditary HLH
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Biological markers 6. Low or absent NK cell activity
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8. sIL-2R  2400 U/mL
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